Dilip Shanghvi

Dilip Shanghvi 5w
Career news reported

Sun Pharma posts double-digit Q1 growth as India business jumps 16%

Sun Pharmaceutical, led by founder-chairman Dilip Shanghvi, reported consolidated revenue growth of about 10% year-on-year for the first quarter of FY27, with its India formulation business up 16% and global innovative medicines up nearly 13%, according to Business Today. The company kept EBITDA margins near 29% and said its pending Organon acquisition remains on track to close in the fourth quarter of FY27.

source: Business Today

Dilip Shanghvi 6w
Career news reported

Organon shareholders approve Sun Pharma takeover

Organon & Co. stockholders voted on July 24, 2026 to approve their merger with Shanghvi's Sun Pharma, clearing a major hurdle for the roughly $11.75 billion enterprise-value deal, Outlook Business reported. Sun Pharma said it expects to close the acquisition by early 2027, subject to regulatory approvals.

source: Outlook Business